Overview

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2029-07-19

Target enrollment:

Participant gender:

Summary

This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of surufatinib and tislelizumab in combination with concurrent chemoradiotherapy, followed by consolidation therapy with tislelizumab plus surufatinib, in patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Radiotherapy
surufatinib
tislelizumab